Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
obesity drugs
Biotech
Lilly's oral GLP-1 tied to 12% weight loss in phase 3 trial
Lilly is now headed toward regulators, angling to submit approval applications for the next-gen obesity asset by the end of 2025.
Gabrielle Masson
Aug 7, 2025 6:30am
Terns vows to stop funding metabolic disease trials beyond 2025
Aug 6, 2025 6:20am
Mice given a brain protein lost weight without getting nauseous
Jul 24, 2025 7:00am
Roche axes Carmot obesity asset, 3 cancer drugs in R&D clear-out
Jul 24, 2025 5:00am
Rhythm’s obesity pill trial hits primary goal, sending stock up
Jul 9, 2025 10:21am
MindRank reports 10% weight loss on oral GLP-1 drug in phase 2b
Jun 24, 2025 10:06am
